Table 1.
Phase II trials with eribulin mesylate in metastatic breast cancer patients
| Trial | N | ORR (%) | CBR (%) | Median DOR (months) | Median PFS (months) | Median OS (months) | 6-month PFS (%) | 6-month OS (%) | Grade 3/4 toxicities |
|---|---|---|---|---|---|---|---|---|---|
| Vahdat et al26 | 87 | 11.5 | 17.2 | 5.6 | 2.6 | 9 | 25.9 | 67.8 | Neutropenia, leukopenia, fatigue |
| Cortes et al27 | 269 | 9.3 | 17.1 | 4.1 | 2.6 | 10.4 | 12.4 | 72.3 | Neutropenia, leukopenia, fatigue |
| Iwata et al28 | 81 | 21.3 | 27.5 | 3.9 | 3.7 | 11 | 20.1 | 72.3 | Neutropenia, leukopenia, febrile neutropenia |
Abbreviations: ORR, overall objective response rate; CBR, clinical benefit rate; DOR, duration of response; PFS, progression-free survival; OS, overall survival.